^
Association details:
| Biomarker: | PD-L2 overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | capecitabine (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5271 - Correlative analysis of RNA biomarkers for adjuvant capecitabine benefit in the CIBOMA/2004-01phase III clinical trial of triple negative breast cancer patients
Published date:
03/09/2022
Excerpt:
Tumors above the median for genes involved in immune response (PDL2, CCR5)...were significantly associated with favorable survival rates on the capecitabine arm (HRcapecitabine ranged between 0.51-0.60; p=0<0.05)….In this prespecified correlative analysis of the CIBOMA trial, PAM50 non-basal status and the mast cell metagene identified early-stage TNBC patients most likely to benefit from adjuvant capecitabine.
